Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Dimerix stock

DXB.AX
AU000000DXB7

Price

0.40
Today +/-
-0.00
Today %
-1.26 %
P

Dimerix stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Dimerix stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Dimerix stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Dimerix stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Dimerix's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Dimerix Stock Price History

DateDimerix Price
11/1/20240.40 undefined
10/31/20240.40 undefined
10/30/20240.41 undefined
10/29/20240.40 undefined
10/28/20240.42 undefined
10/25/20240.42 undefined
10/24/20240.41 undefined
10/23/20240.43 undefined
10/22/20240.45 undefined
10/21/20240.45 undefined
10/18/20240.46 undefined
10/17/20240.48 undefined
10/16/20240.48 undefined
10/15/20240.50 undefined
10/14/20240.48 undefined
10/11/20240.45 undefined
10/10/20240.45 undefined
10/9/20240.42 undefined
10/8/20240.40 undefined
10/7/20240.38 undefined

Dimerix Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dimerix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dimerix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dimerix’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dimerix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dimerix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dimerix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dimerix’s growth potential.

Dimerix Revenue, EBIT and net profit per share

DateDimerix RevenueDimerix EBITDimerix Net Income
2025e29.16 M undefined24.66 M undefined33.19 M undefined
2024583,480 undefined-16.92 M undefined-17.08 M undefined
202336,790 undefined-13.75 M undefined-13.8 M undefined
20222,370 undefined-10.44 M undefined-10.49 M undefined
20211,510 undefined-6.32 M undefined-6.37 M undefined
20202,700 undefined-4.49 M undefined-4.49 M undefined
201918,110 undefined-2.89 M undefined-2.89 M undefined
201820,180 undefined-3.32 M undefined-3.32 M undefined
201718,280 undefined-1.76 M undefined-1.76 M undefined
201645,310 undefined-1.28 M undefined-5.25 M undefined
201531,420 undefined-579,540 undefined-679,540 undefined
201440,000 undefined-550,000 undefined-530,000 undefined
2013130,000 undefined-340,000 undefined-520,000 undefined
2012160,000 undefined-260,000 undefined-390,000 undefined
2011480,000 undefined10,000 undefined10,000 undefined
201060,000 undefined-350,000 undefined-350,000 undefined
200930,000 undefined-480,000 undefined-4.13 M undefined
2008800,000 undefined-2.7 M undefined-3.56 M undefined
2007680,000 undefined-2.47 M undefined-2.42 M undefined
200670,000 undefined-3.02 M undefined-11.16 M undefined
20052.41 M undefined-500,000 undefined-600,000 undefined

Dimerix Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e
54222000000000000000000029
--20.00-50.00----------------------
40.0025.0050.0050.0050.00--------------------
2111100000000000000000000
-50000-3-2-20000000-1-1-3-2-4-6-10-13-1624
-100.00-----------------------82.76
-40000-11-2-3-4000000-5-1-3-2-4-6-10-13-1733
-------81.8250.0033.33--------80.00200.00-33.33100.0050.0066.6730.0030.77-294.12
0.780.080.120.160.581.081.362.695.3610.2210.2210.2213.2917.3820.9171.485.24115.42158.61174.56201.38299.52325.53452.910
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Dimerix Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Dimerix is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                               
0.250.340.050.142.241.130.450.120.371.161.461.181.751.22.932.022.246.283.567.795.259.637.9922.14
0.630.450.290.35000.060.0600000.010.010.030.50.620.981.372.570000.53
0.180.090.030.050.170.030.090.020.010.0100000000000008.99
46027025028000802100000000000000000
0005700050190001010000000030.35161.37473.53205.77257.74
1.521.150.621.392.411.160.730.60.381.171.471.191.761.212.962.522.877.264.9410.395.4110.18.231.92
460300210110102020200000004.862.213.270.392.621.231.428.6127.87162.43
00.070.010.0101.80000.4300000000000000
000000000000000000004.016.399.550
00.050.040.338.1103.321.830000000000000000
000000000000000000000000
3003203400050000000000000000000
0.760.740.60.458.121.873.341.8500.4300000000004.016.49.580.16
2.281.891.221.8410.533.034.072.450.381.61.471.191.761.212.972.532.877.264.9410.399.4216.517.7832.08
                                               
4.715.145.296.3917.4420.2421.324.4827.8329.429.429.430.2930.2931.5610.9213.0120.2920.4728.3428.3950.955.4983.38
000000000000000000000000
-4.07-4.86-5.86-6.56-7.16-17.55-19.88-23.39-27.49-27.84-27.83-28.22-28.58-29.11-28.78-8.68-10.38-13.43-16.27-20.58-26.92-36.47-49.53-65.19
0000000-0.090000000000000000
000000000000000000000000
0.640.28-0.57-0.1710.282.691.4210.341.561.571.181.711.182.782.242.636.864.27.761.4714.425.9618.19
1.481.021.141.110.230.330.510.370.040.040.030.030.050.030.180.260.210.360.721.512.791.865.672.53
0000010405010000000000000000
408080700000000001016.2718.1731.6642.318.3929.9665.25108.84132.79751.26
0.010.010.010.010.010.010.480000000000001.065.0505.940
0.060.2200000.471.02000000000000.030.040.050.020.08
1.591.331.231.190.240.351.51.440.050.040.030.030.050.040.190.280.240.410.742.637.952.0211.763.36
0.020.270.530.78001.16000000000000000.0200.07
000000000000000000000000
0.030.020.020.02000000000000000000.030.0410.46
0.050.290.550.8001.16000000000000000.050.0410.53
1.641.621.781.990.240.352.661.440.050.040.030.030.050.040.190.280.240.410.742.637.952.0711.7913.89
2.281.91.211.8210.523.044.082.440.391.61.61.211.761.222.972.532.877.264.9410.399.4216.517.7632.08
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Dimerix provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Dimerix's financial health and stability.

Assets

Dimerix's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Dimerix must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Dimerix after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Dimerix's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (k)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00000000000000000000-6-10-13
00000000000000000000000
00000000000000000000000
00000000000000000011346
00000000000000000000000
00000000000000000000000
00000000000000000000000
0000-1-2-1-2-1000000-1-1-3-2-4-6-13-12
00000000000000000000000
10000000000000020000000
10000000000000020000000
00000000000000000000000
-1000000-1-1000000000013-16
000131033100102027080205
-1001211221001020270831711
----------------------1.00-
00000000000000000000000
00000-3,000-2,000-2,000-1,00000-1,000001,0000-2,0000-6,000-1,000-12,000-13,000-20,000
0-0.68-0.59-1.26-1.57-2.03-1.66-2.46-1.87-0.37-0.33-0.23-0.31-0.57-0.55-1.38-1.87-3.23-2.76-4.72-6.37-13.45-12.73
00000000000000000000000

Dimerix stock margins

The Dimerix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dimerix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dimerix.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dimerix's sales revenue. A higher gross margin percentage indicates that the Dimerix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dimerix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dimerix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dimerix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dimerix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dimerix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dimerix Margin History

Dimerix Gross marginDimerix Profit marginDimerix EBIT marginDimerix Profit margin
2025e60 %84.56 %113.8 %
202460 %-2,900.27 %-2,926.42 %
202360 %-37,362.38 %-37,517.86 %
202260 %-440,668.8 %-442,640.53 %
202160 %-418,674.17 %-421,968.85 %
202060 %-166,450 %-166,450 %
201960 %-15,937.16 %-15,937.16 %
201860 %-16,450.6 %-16,450.6 %
201760 %-9,619.97 %-9,619.97 %
201660 %-2,824.08 %-11,596.73 %
201560 %-1,844.49 %-2,162.76 %
201460 %-1,375 %-1,325 %
201360 %-261.54 %-400 %
201260 %-162.5 %-243.75 %
201160 %2.08 %2.08 %
201060 %-583.33 %-583.33 %
200960 %-1,600 %-13,766.67 %
200860 %-337.5 %-445 %
200783.82 %-363.24 %-355.88 %
2006100 %-4,314.29 %-15,942.86 %
200555.19 %-20.75 %-24.9 %

Dimerix Stock Sales Revenue, EBIT, Earnings per Share

The Dimerix earnings per share therefore indicates how much revenue Dimerix has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dimerix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dimerix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dimerix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dimerix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dimerix Revenue, EBIT and net profit per share

DateDimerix Sales per ShareDimerix EBIT per shareDimerix Earnings per Share
2025e0.05 undefined0 undefined0.06 undefined
20240 undefined-0.04 undefined-0.04 undefined
20230 undefined-0.04 undefined-0.04 undefined
20220 undefined-0.03 undefined-0.04 undefined
20210 undefined-0.03 undefined-0.03 undefined
20200 undefined-0.03 undefined-0.03 undefined
20190 undefined-0.02 undefined-0.02 undefined
20180 undefined-0.03 undefined-0.03 undefined
20170 undefined-0.02 undefined-0.02 undefined
20160 undefined-0.02 undefined-0.07 undefined
20150 undefined-0.03 undefined-0.03 undefined
20140 undefined-0.03 undefined-0.03 undefined
20130.01 undefined-0.03 undefined-0.04 undefined
20120.02 undefined-0.03 undefined-0.04 undefined
20110.05 undefined0 undefined0 undefined
20100.01 undefined-0.03 undefined-0.03 undefined
20090.01 undefined-0.09 undefined-0.77 undefined
20080.3 undefined-1 undefined-1.32 undefined
20070.5 undefined-1.82 undefined-1.78 undefined
20060.06 undefined-2.8 undefined-10.33 undefined
20054.16 undefined-0.86 undefined-1.03 undefined

Dimerix business model

Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.com.

Dimerix SWOT Analysis

Strengths

Dimerix Ltd possesses several strengths that contribute to its success:

  • Strong intellectual property portfolio, providing a competitive advantage in the market.
  • Advanced technology and expertise in the development of innovative therapeutics.
  • Diverse and experienced management team with a track record of successful commercialization.
  • Strategic partnerships with leading pharmaceutical companies, enhancing research and development opportunities.
  • Strong financial position and access to capital, facilitating future growth and expansion.

Weaknesses

Despite its strengths, Dimerix Ltd faces certain weaknesses that need to be addressed:

  • Relatively small size and limited resources compared to established competitors.
  • Dependency on key partnerships, creating the risk of potential disruptions or conflicts.
  • Limited market presence and brand recognition, making it challenging to attract customers and investors.

Opportunities

Dimerix Ltd can capitalize on various opportunities to drive growth and achieve success:

  • Expanding market demand for novel therapeutics, particularly in the field of [specific therapeutic area].
  • Potential collaborations with academic institutions and research organizations to access new technologies and ideas.
  • Growing interest from investors in the biotech sector, providing potential funding opportunities.

Threats

Dimerix Ltd should be aware of the following threats that may hinder its progress:

  • Intense competition from both established pharmaceutical companies and emerging biotech firms.
  • Regulatory challenges and strict approval processes for new therapeutics.
  • Potential disruptions in the supply chain or manufacturing processes, impacting product availability.
  • Market volatility and economic uncertainties, affecting investor confidence and funding availability.

Dimerix Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Dimerix historical P/E ratio, EBIT multiple, and P/S ratio

Dimerix shares outstanding

The number of shares was Dimerix in 2023 — This indicates how many shares 325.529 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dimerix earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dimerix's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dimerix’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dimerix's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dimerix stock splits

In Dimerix's history, there have been no stock splits.
Dimerix does not pay out any dividends.
Dimerix does not pay out any dividends.
Dimerix does not pay out any dividends.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Dimerix.

Dimerix shareholders

%
Name
Stocks
Change
Date
7.18045 % Meurs (Peter Fletcher)40,018,96408/20/2024
6.39844 % Skiptan Pty. Ltd.35,660,542375,0008/20/2024
1.80877 % Precision Opportunities Fund Ltd.10,080,87510,080,8758/20/2024
1.31286 % Bavaria Bay Pty. Ltd.7,316,99208/20/2024
0.98415 % De Ravin (Richard Stanley)5,485,0001,285,0008/20/2024
0.98339 % Yodambao Pty. Ltd.5,480,732-881,8718/20/2024
0.97787 % Coates (Melinda Jane)5,450,000450,0008/20/2024
0.80742 % Scott (Julie Maree)4,500,00075,0008/20/2024
0.80742 % Scott (Philip Robert)4,500,00075,0008/20/2024
0.77261 % Coates (Andrew Joseph)4,306,000-5,5008/20/2024
1
2

Dimerix Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
IQVIA Holdings Stock
IQVIA Holdings
SupplierCustomer0,12-0,060,540,720,67-0,40
1

Most common questions regarding Dimerix

What values and corporate philosophy does Dimerix represent?

Dimerix Ltd represents a set of values and a corporate philosophy that emphasize innovation, scientific excellence, and patient-centered healthcare solutions. With a focus on developing novel therapies for unmet medical needs, Dimerix is committed to enhancing the lives and treatment options for patients. Through collaboration, research, and the application of advanced technology, the company strives to deliver high-quality pharmaceutical products and make a positive impact in the healthcare industry. Dimerix Ltd's dedication to scientific rigor, customer satisfaction, and improving patient outcomes sets a strong foundation for its growth and success in the market.

In which countries and regions is Dimerix primarily present?

Dimerix Ltd is primarily present in Australia.

What significant milestones has the company Dimerix achieved?

Dimerix Ltd has achieved several significant milestones. The company successfully completed its Phase 2 clinical trials for DMX-200, its lead drug candidate. Dimerix also received Orphan Drug Designation from the FDA for DMX-200 in primary Focal Segmental Glomerulosclerosis (FSGS) patients. Additionally, the company secured important partnerships and collaborations with renowned organizations and experts in the field. Dimerix's commitment to innovation and clinical advancement has positioned the company as a leader in the biopharmaceutical industry.

What is the history and background of the company Dimerix?

Dimerix Ltd is a renowned Australian biopharmaceutical company that specializes in the development and commercialization of innovative therapies. Established in [year], Dimerix has a strong history of cutting-edge research and collaboration with leading scientific institutions. The company's primary focus lies in developing novel treatments for unmet medical needs, particularly in the field of kidney disease and cancers. Dimerix's expertise lies in its proprietary drug development platform, enabling the identification and optimization of potential drug candidates. With a dedicated team of experts, Dimerix is committed to advancing scientific breakthroughs and improving the lives of patients worldwide.

Who are the main competitors of Dimerix in the market?

The main competitors of Dimerix Ltd in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services as Dimerix Ltd. However, Dimerix Ltd stands out due to its unique offerings and strong market presence. Despite facing competition, Dimerix Ltd continues to solidify its position as a market leader through innovation, strategic partnerships, and consistent growth.

In which industries is Dimerix primarily active?

Dimerix Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Dimerix?

Dimerix Ltd is an Australian-based biopharmaceutical company specializing in the development of innovative therapies. The business model of Dimerix revolves around identifying and advancing novel drug candidates that target diseases with high unmet medical needs. By utilizing their proprietary technology platforms and expertise in drug discovery, Dimerix aims to provide effective treatments for patients suffering from conditions such as chronic kidney disease and cancer. Through strategic collaborations and partnerships, Dimerix strives to facilitate the development and commercialization of their potential therapies, ultimately improving patients' lives and driving value for their stakeholders.

What is the P/E ratio of Dimerix 2024?

The Dimerix P/E ratio is -10.48.

What is the P/S ratio of Dimerix 2024?

The Dimerix P/S ratio is 306.61.

What is the Quality Investing of Dimerix?

The Quality Investing for Dimerix is 7/10.

What is the revenue of Dimerix 2024?

The Dimerix revenue is 583,480 AUD.

How high is the profit of Dimerix 2024?

The Dimerix profit is -17.08 M AUD.

What is the business model of Dimerix

Dimerix Ltd is a global biotech company specialized in identifying and developing new therapeutics for serious diseases. The company utilizes an innovative strategy that uses G-Protein Coupled Receptors (GPCRs) as targets for drug development. Their business model focuses on developing both their own drug candidates and customized solutions for clients. They employ various platform technologies and tools to analyze the functioning of GPCRs and their interaction with other proteins in signaling pathways. Dimerix offers a range of molecular tools that can be used for identifying new drug candidates and validating targets. Their main products include specialized screening kits that modulate the GPCR signaling pathway and facilitate drug identification. These kits are sold to pharmaceutical and biotech companies as well as academic research institutions. Dimerix also provides customized services tailored to the needs of clients, ranging from identifying potential drug candidates to evaluating the efficacy and toxicity of existing drug candidates. These customized services are primarily sold to pharmaceutical and biotech companies involved in their own drug development. Another important aspect of Dimerix's business model is collaboration with other companies and research institutions. Dimerix works closely with partners to develop new drug candidates and target validation solutions. An example of such collaboration is the partnership with pharmaceutical company Merck KGaA to develop new immuno-oncology drugs. Dimerix has a strong financial position and has successfully completed numerous financing rounds to expand its product range and services. The company also has a strong intellectual property position secured through patents and licensing agreements. In summary, Dimerix's business model is focused on identifying and developing novel drugs for serious diseases. The company utilizes innovative platform technologies and tools to analyze GPCR signaling pathways and identify new targets. Dimerix offers both their own products and customized services to support clients in drug development. With close collaboration with partners and a strong financial position, the company is well positioned to advance its mission and provide innovative solutions for patients.

What is the Dimerix dividend?

Dimerix pays a dividend of 0 AUD distributed over payouts per year.

How often does Dimerix pay dividends?

The dividend cannot currently be calculated for Dimerix or the company does not pay out a dividend.

What is the Dimerix ISIN?

The ISIN of Dimerix is AU000000DXB7.

What is the Dimerix ticker?

The ticker of Dimerix is DXB.AX.

How much dividend does Dimerix pay?

Over the past 12 months, Dimerix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dimerix is expected to pay a dividend of 0 AUD.

What is the dividend yield of Dimerix?

The current dividend yield of Dimerix is .

When does Dimerix pay dividends?

Dimerix pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dimerix?

Dimerix paid dividends every year for the past 0 years.

What is the dividend of Dimerix?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dimerix located?

Dimerix is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dimerix kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dimerix from 10/29/1999 amounting to 0.008 AUD, you needed to have the stock in your portfolio before the ex-date on 9/24/1999.

When did Dimerix pay the last dividend?

The last dividend was paid out on 10/29/1999.

What was the dividend of Dimerix in the year 2023?

In the year 2023, Dimerix distributed 0 AUD as dividends.

In which currency does Dimerix pay out the dividend?

The dividends of Dimerix are distributed in AUD.

All fundamentals about Dimerix

Our stock analysis for Dimerix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dimerix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.